Cerebral accumulation of the amyloid β-peptide (Aβ) is believed to play a key role in the pathogenesis of Alzheimer's disease (AD). Because Aβ is produced from the proteolysis of amyloid β-protein precursor (APP) by β-and γ-secretases, these enzymes are considered important drug targets for AD. The authors have developed a luciferase-based reporter system that can identify new molecules that inhibit APP processing in a high-throughput manner. Such molecules can help in understanding the biology of APP and APP processing and in developing new drug prototypes for AD. In this system, APP is fused on its Cterminus with Gal4-VP16, a chimeric yeast-viral transcription activator, and luciferase is under control of the yeast Gal4 promoter. Compounds that modulate the luciferase signal may affect the secretases directly, interact with modifiers of these proteases, or interact with APP directly. The authors successfully interfaced this assay with a high-throughput screen, testing 60,000 compounds with diverse chemical structures. In principle, this sensitive, specific, and quantitative assay may be useful for identifying both inhibitors and stimulators of APP processing. (Journal of Biomolecular Screening 2005:1-12) ducing a conformational change that results in release from the TO and derepression of APP-GV. The principle of this assay is schematically explained in Figure 3 . In the absence of inhibitor, cleav-age by α-or β-secretase will result in release of the soluble ectodomain of APP-GV (APP-α or APP-β) and membrane-bound hybrid protein C83-GV (C83 fragment of APP fused with Gal4-
INTRODUCTION
H ISTOLOGICAL, BIOCHEMICAL, AND GENETIC EVIDENCE strongly implicates the accumulation of amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer's disease (AD). Autosomal dominant mutations in genes encoding the amyloid precursor protein (APP), presenilin-1 and presenilin-2 (PS1 and PS2), cause rare familial forms of Alzheimer's disease (FAD) 1,2 that, aside from their unusually early age of onset (<65 years), are indistinguishable from the predominant sporadic form. All of these mutations affect the metabolism of APP, a type I transmembrane protein that is the precursor of the Aβ peptides that aggregate in senile plaques characteristic of AD. Aβ is produced from the APP by the sequential action of 2 proteases, β-and γ-secretases ( Fig. 1) . First, βsecretase, a membrane-anchored aspartyl protease, sheds the large lumenal/extracellular ectodomain of APP (abbreviated as APP-β).
The remaining membrane-bound 99-residue C-terminal fragment (CTF), C99, then serves as a substrate for γ-secretase, which catalyzes an unusual proteolysis within the transmembrane region to generate Aβ and release the cytosolic tail of APP (APP intracellular domain, AICD). Alternatively, the ectodomain of APP is shed by α-secretase releasing APP-α and generating an 83residue membrane-associated C-terminal fragment (C83). This transmembrane remnant C83 is also a substrate for γ-secretase, which generates an N-terminally truncated version of Aβ called p3 and AICD (Fig. 1) . Although most of all Aβ isoforms produced is a 40-residue peptide (Aβ40), 10% of total Aβ is extended by 2 residues on the C-terminus. This peptide (Aβ42), which is known to be selectively enhanced by AD-causing PS mutations, is much more prone to aggregation and fibril formation 3 and forms the core of the senile plaques of AD.
Because production of Aβ is mediated by β-and γ-secretases, these enzymes are considered important targets for therapeutic intervention. 5 α-Secretase activity appears to be mediated by the disintegrin and metalloprotease (ADAM) family members TACE and ADAM-10. 6 β-Secretase has been identified as a novel membrane-bound aspartyl protease. 7 The definitive identification of γ-secretase has been elusive, but considerable evidence suggests that it is a multiprotein membrane protease complex consisting of PS (the catalytic component), nicastrin, Aph-1, and Pen-2. 8 This complex (γ-secretase) of 4 integral membrane proteins has resisted purification efforts that would allow crystallization. In the absence of purified enzyme and a crystal structure, studies with small organic inhibitors have played a prominent role in understanding the nature and role of γ-secretase. [9] [10] [11] [12] [13] The function of APP and its proteolytic processing is still unknown. However, although the functions of the APP ectodomain remain elusive, increasing evidence suggests that its cytoplasmic domain is the center of a complex network of interactions with several proteins that are involved in vesicle transport and signal transduction. [14] [15] [16] [17] The evident complexity of this protein-protein interaction network suggests that APP could be a multifunctional molecule that anchors several different oligomeric complexes close to the membrane, possibly in specific subdomains such as caveolae, 18 and/or that APP regulates the availability of these complexes in their final destination, upon APP cleavage and detachment of the APP cytoplasmic domain from the membrane.
Elucidation of the mechanisms underlying the proteolysis of APP, leading to effective therapeutics for AD, has depended critically on the development of sensitive, reliable, and accessible assays for quantifying cleavage products in biological samples. More recently, separate assays for directly measuring the activity of the secretases (α, β, and γ) have been described; in general, assays for assessing the inhibition of α-, β-, and γ-secretases include high-performance liquid chromatography (HPLC), 19 enzymelinked immunosorbent assay (ELISA), and Western blot, 10, 20, 21 which are quite cumbersome and expensive and therefore illsuited for high-throughput screening (HTS).
To overcome these difficulties and to decrease the time involved, we have developed a novel cell-based screening method. For developing this screen, we used T-REx 293 cells 22 that are derived from the parental human cell line HEK 293, which has predominantly endogenous α-and γ-secretase activities and some βsecretase activity. T-REx 293 cells contain a tetracycline-regulated mammalian expression vector (pc DNA 5/TR), which constitutively expresses the tetracycline repressor protein (TetR) ( Fig. 2a ). TetR recognizes regulatory elements from the Escherichia coli Tn10-encoded tetracycline (Tet) resistance operon. 23 Furthermore, the T-REx 293 cells were cotransfected with (1) a plasmid construct (pc DNA 5/TO) having a tetracycline operator (TO) and ligated with DNA encoding full-length APP695 fused with Gal4-VP16 (GV) at its C-terminus, resulting in APP-Gal4-VP16 (abbreviated as APP-GV and plasmid as APP-GV/TO), and (2) a Gal4driven luciferase reporter gene (abbreviated as Gal4-Luc) ( Fig.  2a ). GV is a chimeric transcription factor having 2 domains: a DNA binding domain (Gal4) from yeast and a viral activation domain (VP16). Because there is no Gal4-like protein in mammalian cells, the luciferase reporter gene with a synthetic promoter UAS carrying Gal4-binding sites is inactive in normal cells. However, in cells expressing the GV fusion protein, the VP16 activation domain is brought to the promoter by the Gal4 binding sites, thus activating transcription of luciferase.
Because the T-REx 293 cells have TetR as well as APP-GV under control of the tetracycline operator, the expression of APP-GV can be controlled by tetracycline ( Fig. 2b ). In the absence of tetracycline, the homodimer of TetR binds to the TO, repressing the transcription of APP-GV. Added tetracycline binds to TetR, 22 in-FIG. 1. Processing of amyloid precursor protein (APP). First, α-or β-secretase sheds the large lumenal/extracellular ectodomain of APP (abbreviated as APP-α or APP-β, respectively). The remaining membrane-bound 83 (C83) or 99-residue (C99) C-terminal fragment (CTF) then serves as a substrate for γ-secretase, which catalyzes an unusual proteolysis within the transmembrane region to generate p3 or Aβ, respectively, and release the cytosolic tail of APP (APP intracellular domain [AICD]).
FIG. 2.
(a) Development of the stable AP-GL-T16 cell line. The parent cell line, T-REx 293, has a tetracycline-regulated mammalian expression vector (pc DNA 5/TR), which constitutively expresses the tetracycline repressor protein (TetR) that recognizes regulatory elements from the Escherichia coli Tn10-encoded tetracycline (Tet) resistance operator. T-REx 293 cells were cotransfected with (1) a plasmid construct encoding full-length APP695 fused with Gal4-VP16 (GV) at its C-terminus, resulting in APP-GV under the control of the tetracycline operator (APP-GV/TO), and (2) a Gal4-driven luciferase reporter gene (abbreviated as Gal4-Luc). (b) In the absence of tetracycline, the regulatory plasmid (pc DNA 5/TR) produces a tetracycline repressor protein (TetR) that has a strong binding affinity for the 2 tetracycline operator (TO) sites in the inducible expression vector (APP-GV/TO) (pc DNA 5/TO ligated with APP-GV), and so the transcription of APP-GV is repressed. The addition of tetracycline results in its binding to the TetR repressor protein followed by a conformational change and then its release from the TO, and the expression of APP-GV is thereby derepressed. APP = amyloid precursor protein; AICD = APP intracellular domain; CMV = cytomegalovirus. a b VP16) or C99-GV (C99 fragment of APP fused with Gal4-VP16) ( Fig. 2 ), respectively. Subsequent proteolysis of these membranebound remnants by γ-secretase then liberates the AICD, along with the fused GV transcription factor (AICD-GV). The released AICD-GV then translocates to the nucleus due to a nuclear localization sequence in GV, and GV activates transcription of the Gal4driven luciferase reporter gene. In general, inhibition of APP proteolysis would reduce the expression of luciferase. Because the αpathway by far predominates over the β-pathway in HEK cells, βsecretase inhibitors are expected to have very little effect on the generation of luciferase. However, no cell-permeable inhibitors of β-secretase were available to check this notion.
Because this assay uses full-length APP and is cell based, inhibitors of the α-and γ-secretase pathways can be identified: compounds that are not direct inhibitors of these secretases but affect processing of APP by other mechanism(s) can also be discovered. Such compounds could be valuable tools for understanding the bi-ology of APP and APP-processing secretases, particularly for elucidating how these secretases are regulated, and may be important prototype drugs that specifically modulate APP processing without affecting other secretase substrates. In this report, we demonstrate the development and successful interfacing of this assay with automated instrumentation for high-throughput screening (HTS).
MATERIALS AND METHODS

Cell culture conditions
All cells were cultured at 37°C in the presence of 5% CO 2 . T-REx HEK 293 cells were purchased from Invitrogen (Los Angeles, CA) and were maintained according to the manufacturer's instructions in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Los Angeles, CA) containing L-Gln (Invitrogen) and 10% fetal bovine serum (Sigma, St. Louis, MO). Stably transfected FIG. 3. Principle of the amyloid precursor protein (APP) reporter assay. Full-length APP695 fused with Gal4-VP16 was used as substrate for α-, β-, and γ-secretases. In the absence of inhibitors, ectodomain shedding of APP by α-or β-secretases generates 83-or 99-residue membrane-associated C-terminal fragments. C83-GV and C99-GV, on further processing by γ-secretase, release AICD-GV, which then translocates to the nucleus. Gal4 then binds with the UAS promoter, and VP16 initiates synthesis of luciferase. Compounds that modulate the luciferase signal may affect the secretases directly, interact with modifiers of these proteases, or interact with APP directly. AICD = APP intracellular domain. cells were cultured in DMEM supplemented with 250 µg/mL zeocin, 200 µg/mL hygromycin, 5 µg/mL blasticidin (all from Invitrogen), 10% fetal bovine serum, and L-Gln (DMEM-zeohygro-blast).
Generation of DNA constructs
APP-GV (DNA encoding full-length APP695 fused at its Cterminus with Gal4-VP16), ligated into pcDNA3.1 (APP-GV/3.1) and pFR-Luc (encoding luciferase under control of 5 tandem repeats of the Gal4 binding site), were gifts from Dr. Mark Bothwell (University of Washington, Seattle). Briefly, the cDNA sequence encoding the full-length APP695 was amplified by PCR to incorporate a 5′ Xba I site and a 3′ Spe I site, and the composite yeast transcription factor and viral transcription activator Gal4-VP16 was likewise amplified to include a 5′ Spe I site and a 3′ Xba I site. Xba I/Spe I-digested APP695 was ligated in tandem with the Spe I/ Xba I-cleaved Gal4-VP16 and Xba I-cleaved pcDNA3.1 vector (Invitrogen) to generate the plasmid, with the DNA sequence encoding chimeric APP695-Gal4-VP16 (APP-GV). To generate a tetracycline-inducible construct of APP-GV (APP-GV/TO), the insert containing APP-GV was excised out of the original construct (APP-GV/3.1) with Hind III and Xba I and ligated with Hind III/Xba I-cleaved pc DNA 5/TO vector (Invitrogen).
To generate a Gal4-driven luciferase reporter gene construct that is suitable for stable transfection, we first cleaved the pFR-Luc vector by StyI, and the protrusive ends were converted to blunt ends by Tag DNA polymerase. An additional cleavage of the linearized vector by Nde I released the complete open reading frame of firefly luciferase along with the upstream promoter with Gal4 binding motifs, which was then purified and ligated with the pBudCE4.1 vector (Invitrogen) previously cleaved by Nde I and Sca I. The residual cytomegalovirus (CMV) promoter sequence carried over from original pBudCE4.1 vector was removed by the cleavage of Nde I and Spe I, followed by the conversion of protrusive ends to blunt ends by Tag DNA polymerase and subsequent self-ligation to generate a novel Gal4-promoter (UAS)-driven luciferase reporter construct (Gal4-Luc) containing a zeocin-resistant selection marker.
Transient transfection of mammalian cells
Transfection of T-REx 293 cells was performed by using FuGENE6 transfection reagent. Cells were plated onto 6-well microplates and grown to about 60% to 80% confluency prior to transfection. On the day of transfection, the culture medium was replaced with fresh 2 mL/well of DMEM supplemented with 10% fetal bovine serum (FBS). APP-GV/TO or APP-GV/3.1 (0.5 µg), Gal4-Luc (0.5 µg), and pRL-TK (0.1 µg) were diluted in 100 µL of serum-free DMEM and mixed with 3.3 µL of FuGENE6, followed by incubation at room temperature for 15 min. In this transfection, pRL-TK (Promega), a vector constitutively expressing Renilla luciferase, was included as an internal control to normalize the transfection variation. To the transfection mixture containing APP-GV/3.1 construct or APP-GV/TO was added tetracycline (final concentration 5 µg/mL, with 1% of DMSO), with or without compound E (final concentration 1 µM, with 1% of DMSO), a potent γ-secretase inhibitor. 24 Compound E was prepared following methods described in the literature. 24 The transfection mixture containing DMSO alone (final concentration 1%) was included as control. Transfection mixtures were added dropwise into cell culture medium and incubated at 37°C for 24 h. Transfected cells were harvested with phosphate-buffered saline (PBS) containing 20 mM EDTA and lysed with 100 µL 1× passive lysis buffer (PLB) (Promega). Cell lysates were clarified by centrifugation and subjected to luciferase assay using the Dual Luciferase Assay Reagent Kit (Promega, Madison, WI). Protein content of lysates was determined by the BCA Protein Assay Reagent Kit (Promega).
Generation of stably transfected cell lines
T-REx 293 cells were grown in 10-cm dishes until 50% confluency, as described above. On the day of transfection, the culture medium was replaced with 8 mL DMEM containing 10% FBS. To generate a stable cell line cotransfected with the tetracycline-inducible expression construct of APP-GV (APP-GV/TO) and Gal4-Luc reporter construct, equal amounts of APP-GV/TO (2.5 µg) and Gal4-Luc (2.5 µg) were diluted in 800 µL serum-free DMEM, followed by the addition of 15 µL FuGENE6 transfection reagent and subsequent incubation at room temperature for 15 min. Transfection mixture was then added dropwise into culture medium, and cells were incubated at 37°C for 24 h. Following an additional 24 h of recovery at 37°C in DMEM containing 10% FBS, transfected cells were split 1:10 into 10-cm dishes containing 10 mL DMEM supplemented with 10% FBS, 200 µg/mL hygromycin, 250 µg/mL zeocin, and 5 µg/mL blasticidin (DMEM-HZB) and incubated at 37°C for 7 days. Culture media were replaced every 7 days until distinct colonies were formed. Single colonies resistant to antibiotic selection were isolated individually using cloning cylinders and transferred into 24-well microplates, which were subsequently expanded into 12-well microplates, then 6-well microplates, and eventually 10-cm dishes. Each isolated clone was screened for tetracycline-induced expression of APP-GV and an accompanying luciferase signal that can be attenuated by γ-secretase inhibitor compound E. For this, selected cell lines were plated into 96-well microplates in DMEM-HZB media (total volume = 80 µL containing 8000 cells). After 24 h of incubation, fresh media (20 µL) containing 5 µg/mL (final concentration) of tetracycline in the presence or absence of 1 µM compound E 24 were added. Wells containing only 1% of DMSO as control were also included. The cells were then incubated for an additional 24 h. The addition of reagents for both luciferase assays was accomplished simultaneously by using the Bright-Glo Luminescent substrates (Promega), as described in the manufacturer's instructions. Luciferase signals were determined using a Victor microplate luminometer (PerkinElmer). Two replicates of each condition were done, and bar graphs were plotted using Sigma plot software. The optimal cell line exhibited the highest tetracyclineinduced luciferase signal that could be suppressed by compound E down to the basal level (comparable to the luciferase signal obtained in the absence of tetracycline induction). Based on this criterion, clone AP-GL-T16 was selected.
Determination of effect of number of cells on luciferase signal
The assay was preformed with the AP-GL-T16 clone. Serially diluted cells, starting from 20,000 cells per well (80 µL), were added to 96-well plates. After 24 h of incubation, 20 µL of fresh media with/without 5 µg/mL of tetracycline (final concentration) was added. Two replicates for each condition were used. After 24 h of further incubation, 100 µL/well of luciferase substrate was added, and luminescence was checked on an LJL Analyst (Molecular Device).
EC 50 determination with tetracycline
Cells were trypsinized using trypsin-EDTA (Invitrogen) and harvested by centrifugation at 1510g. The pellet was then resuspended with DMEM-HZB. The density of cells was determined with a hematocytometer, and cells (500 cells/µL) were transferred at 40 µL/well into 384-well Nunc cell culture plates. Cells were incubated at 37°C in a CO 2 incubator for 24 h. Serially diluted tetracycline was added to media starting from a 5-µg/mL concentration on a separate plate. For each concentration, 10 wells were used. For negative control, no tetracycline was added to media. On the second day, 10 µL/well of media with/without tetracycline was added. After an additional 48 h of incubation, the plates were brought to room temperature, and 50 µL of luciferase substrate was added. The luminescence was then read using an LJL Analyst (Molecular Device).
IC 50 determination of a -secretase inhibitor
Serial 3-fold dilutions of compound E, a potent inhibitor of γsecretase, starting at 3 µM final concentration, were prepared on a separate plate using media with tetracycline, and 10 µL of each was added to 384-well Nunc white plates containing cells (final concentration of tetracycline was 1 µg/mL). Ten replicates were used for each concentration, and the experiment was performed 3 times. The plates were further incubated for 48 h after tetracycline addition. After bringing the temperature down to room temperature, 50 µL of luciferase substrate/well was added and mixed, and luminescence was recorded with an LJL Analyst (Molecular Device).
HTS for modulators of APP processing
Cells were trypsinized using trypsin-EDTA (Invitrogen) and harvested by centrifugation at 1510 × g. The pellet was then resuspended with DMEM-HZB. The density of cells was determined with a hematocytometer, and cells (500 cells/µL) were transferred at 40 µL/well into 384-well Nunc cell culture plates using a cell dispenser (Multidrop 384, Thermo Labsystems). Cells were incubated at 37°C in a CO 2 incubator for 24 h. HTS was carried out using a Beckman Sagian Core system consisting of a Biomek Fx pipette station, plate carousel, plate shaker, plate washer, and cytomate incubator with temperature control from 15 to 50°C. Different compound libraries (total of 60,000 compounds) available for screening consisted of a collection of (1) drugs approved by the Food and Drug Administration (FDA); (2) In each screen, a full plate control (halfpositive control and half-negative control) was used as quality controls for that screen. The plates containing the spotted compounds and controls were covered with plate sealers and stored at -20°C until the day of screening (generally for 24 h). Then, 40 µL/well of DMEM medium without FBS and containing 20 µg/mL of tetracycline was added to prespotted Greiner 384-well compound plates with controls and shaken. Aliquots of 10 µL/well of media containing compound were transferred to the Nunc assay plates containing 40 µL/well of cells (final concentration of tetracycline is 1 µg/mL) and shaken. Final compound concentration for screening was 1 µM. The plates were incubated at 37°C for 48 h. At the end of treatment, 30 µL/well of cell culture supernatant was transferred into empty Nunc cell culture plates and brought to room temperature. Then, 20 µL/well of Bright-Glo Luminescent substrate (Promega, Madison, WI) was added to the rest of the 20 µL in the Nunc assay plate. The plates were shaken, and luminescence was determined using an LJL Analyst (Molecular Device).
The Z′ factor, a dimensionless statistical characteristic for each plate, was calculated using Excel software according to the method developed by Zhang et al. 25 Z SD pos. control SD neg. control mean pos. contr
where SD pos. control is the standard deviation (n = 16) of the positive control (with tetracycline), SD neg. control is the standard deviation (n = 12) of the negative control (no tetracycline), mean pos. control is the mean (n = 16) of the positive control (containing tet-racycline), and mean neg. control is the mean (n = 12) of the negative control (no tetracycline). From luminescence, the uncorrected inhibition was calculated using the following formula: % Inhibition = 100 × [1 -(luminescence -avg. negative control)/(avg. positive control -avg. negative control)], where avg. negative control is the average luminescence calculated from wells with DMSO alone, and avg. positive control is the average of luminescence from the positive control (containing tetracycline with DMSO). Effect of compounds on cell viability was examined using CytoTox-One™, which is a homogeneous membrane integrity assay (Promega), according to the manufacturer's instructions. Briefly, 30 µL/well of CytoTox-One™ substrate solution (Promega) was added to the Nunc plates containing the cell culture supernatant and shaken. After incubating plates for 30 min, 10 µL/ well of CytoTox-One™ stop solution (Promega) was added, and plates were shaken for 1 min. The fluorescence was read with a Gemini plate reader (Molecular Device) at 590 nm emission after excitation at 560 nm. Percent cell death was calculated on Excel software using the following formula: % Cell death = 100 × (fluorescence -avg. background)/(avg. lysis -avg. background), where avg. background is the average fluorescence calculated from wells with DMSO alone, and avg. lysis is the average fluorescence calculated from lysed cells with detergent (control for total cell death).
Using cell toxicity data, inhibition was then corrected (corrected inhibition) by dividing percent inhibition by the fraction of cell toxicity.
RESULTS
Screening strategy
For developing an assay suitable for HTS, we first ligated APP695-Gal4-VP16 (APP-GV) into the Hind III/Xba I-digested pc DNA 5/TO (inducible expression vector), and the resulting construct (APP-GV/TO) was transfected with the Gal4-driven reporter gene (Gal4-Luc) into T-REx 293 cells (containing regulatory plasmid pc DNA 6/TR, tetracycline-regulated expression system) ( Fig. 2a ). Expression of APP-GV from the inducible expression vector APP-GV/TO should occur only in the presence of tetracycline (Fig. 2b) . Sequential cleavage by α-or β-secretase followed by γ-secretase releases the AICD fused to Gal4-VP16 (AICD-GV), which then translocates to the nucleus and expresses luciferase through specific binding to the promoter region controlling expression of luciferase ( Fig. 3 ). Upon addition of luciferin, the luciferase substrate is converted to oxyluciferin, which is a luminescent molecule. Inhibition of AICD-GV generation by either direct secretase inhibition or inhibition of APP processing by some unknown mechanism(s) should reduce luminescence, and this reduction was used as criterium for selecting inhibitors.
Transient transfection
T-REx 293 cells were transiently cotransfected either with APP-GV/TO and Gal4-Luc or with APP-GV/3.1 and Gal4-Luc. pRL-TK (Promega), a vector constitutively expressing Renilla luciferase, was also included as an internal control to normalize the transfection variation. Promega's Dual-Luciferase Reporter (DLR) Assay System was used for performing dual reporter assays. In the DLR assay, the activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured sequentially from a single sample. The firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent signal. After quantifying the firefly luminescence, this reaction is quenched, and the Renilla luciferase reaction is initiated by simultaneously adding Stop & Glo Reagent to the same tube. The result of firefly luminescence (normalized based on the Renilla signal) plotted and analyzed using Sigma plot software is presented in Figure 4 (representative of 2 experiments) . In the presence of DMSO alone, cells transfected with APP-GV/3.1 showed high luminescence (due to constitutive expression of APP-GV), whereas APP-GV/TO-transfected cells gave a negligible signal. On addition of tetracycline, no further increase in luminescence signal was ob- 
Assay characterization, optimization, and validation
The stable cell line AP-GL-T16, developed by coexpression of APP-GV/TO and Gal4-luc into T-REx 293 cells, was first checked for the intensity and specificity of the luminescence response, as shown in Figure 5 . In the presence of DMSO (1%) alone, very little luciferase signal is observed. The low basal expression of APP in the absence of tetracycline might be due to "leakiness" in the assay (i.e., non-tetracycline-dependent expression) or the presence of minute amounts of tetracycline in FBS (many lots of FBS are known to contain tetracycline, as FBS is generally isolated from cows that have been fed a diet containing tetracycline [Invitrogen manufacturer's instructions]). The wells containing tetracycline (final concentration 5 µg/mL, with 1% DMSO) as the inducing molecule showed a 25-fold increase in luminescence (Fig. 5) . To inhibit the release of AICD-GV from APP-GV, we used 1 µM of compound E). The luciferase signal was inhibited by compound E, suggesting the requirement of AICD-GV for signal generation (Fig. 5, representative of 3 separate experiments) .
To further study the performance of the stable cell line generated, we checked the luciferase signal with respect to the number of cells. For this, we serially diluted the cells in a 96-well format and added fresh media with or without 5 µg/mL of tetracycline. After 24 h of incubation, the luciferase assay was conducted using the "Bright and Glo" (Promega) reagent. We found that luciferase activity is proportional to the cell number ( Fig. 6) .
For studying the effect of different concentrations of tetracycline on the inducible reporter system and to optimize the concentration of tetracycline needed for HTS, a fixed number of cells-20,000/well (total volume = 40 µL)-were plated into 384-well plates. The double-transfected AP-GL-T16 cells were incubated with different dilutions of tetracycline for 48 h (n = 10 for each concentration). The wells without tetracycline served as a negative control. After 48 h of incubation, the plates were brought to room temperature, and luciferase substrate was added. The mean of luminescence from the negative controls was used as the basal value, and this was subtracted from the mean luminescence at each concentration (corrected luminescence). The luminescence (percent control) was calculated by dividing the corrected luminescence for every concentration by the corrected luminescence at the maximal concentration of 5 µg/mL tetracycline (Fig. 7) . The calculated EC 50 (effective concentration in which the luminescence is 50% Bakshi et al. 6 . Effect of the number of cells on luminescence. Serially diluted cells starting from 20,000 with or without a fixed concentration of tetracycline (final concentration 5 µg/mL, with 1% DMSO) were incubated for 48 h in 96-well plates. Two replicates for a particular number of cells were done. The bar graph was plotted in Excel software between the number of cells (x-axis) versus luminescence observed (y-axis). The luciferase activity was found to be proportional to the number of AP-GL-T16 cells. The result is representative of 2 experiments. Error bars represent the standard deviation of 2 replicates. compared to the maximum luminescence reached at 5 µg/mL) of tetracycline is 0.05 µg/mL.
As shown in Figure 7 , almost similar luciferase signals were observed in a dose range of 0.1 to 5 µg/mL of tetracycline. To avoid tetracycline toxicity at higher dosages and to have good difference between inhibition and signal, we selected 1 µg/mL concentration for further studies.
The luciferase reporter assay was further validated quantitatively using different doses of compound E with a fixed concentration of tetracycline (1 µg/mL). The wells with no tetracycline or inhibitor served as a negative control. The IC 50 for the inhibitor was determined by performing a nonlinear regression (using a standard sigmoid 4-parameter equation) on the observed data using the Sigma plot. Compound E inhibited the luciferase signal in a dosedependent manner, with an IC 50 (from 3 separate experiments) of approximately 10 ± 5 nM (Fig. 8 ). The IC 50 of compound E was found to be higher than a previously reported IC 50 (0.3 nM) for lowering Aβ production from APP-transfected cells. 24 This difference might be due to differences in cell lines, expression levels of exogenous APP, or assay conditions.
HTS for modulators of APP processing
The screening was carried out with a library composed of 60,000 structurally diverse chemical compounds that, in general, had the following characteristics 26 : (1) molecular weights less than 600 Daltons, (2) log P (partition coefficient is a constant; it is defined as the ratio of the concentration of the compound in the aqueous phase to the concentration in an immiscible solvent as the neutral molecule) less than 5, (3) fewer than 5 H (hydrogen)-bond donors, and (4) fewer than 10 H-bond acceptors. The compounds were screened at a final concentration of 1 µM. Positive control wells (n = 16) on each plate contained 1 µg/mL of tetracycline as the inducing molecule with 0.8% DMSO, whereas negative control wells (n = 12) included 0.8% DMSO alone. The potent inhibitor of γ-secretase (compound E) at 1 µM concentration was also included in 4 wells per plate. In each screen, a full control plate (halfpositive controls and half-negative controls) was used as quality control for that screen. The Z′ factor, a standard statistical parameter for HTS assays that is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements, was calculated using luminescence values from positive and negative control wells from each plate. Figure 9a -c shows the Z′ factors 25 for 3 screening runs. In Figure 9c , 7 out of 12 plates were found to have a Z′ value below 0.4, which might be due to unhealthy cells on that particular day of the screen. The plates having a Z′ value <0.4 were repeated. Figure 10 represents an example of repeated plates. Of all the plates tested, 80% had a Z′ value of 0.7 to 0.4 and 20% below 0.4. The observed variability in the screen might be due to (1) unhealthy cells on that particular day of screen or (2) the compounds in those plates that were interfering with luminescence.
Because this assay is a cell-based assay and tetracyclineinduced luminescence depends on viable cells, the effect of com- FIG. 8. IC 50 determination of selective γ-secretase inhibitor compound E. The experiment was run in 384-well plates with different concentrations of inhibitor and a fixed concentration of tetracycline (1 µg/ mL). Media with tetracycline and DMSO (1%) served as a positive control. The result was analyzed by fitting the observed data to a 4-parameter nonlinear regression curve in the Sigma plot between concentrations of inhibitor versus percent luminescence of control. The IC 50 is the inhibitory concentration in which luminescence dropped to 50 as compared to control value (the luminescence of wells containing tetracycline alone). In this case, the wells treated with tetracycline alone served as control (100% luminescence). After 48 h of incubation with inhibitor, luciferase activity was found to be blocked in a dose-dependent manner by the inhibitor. The IC 50 value of the inhibitor in this assay (from 3 separate experiments) was 10 ± 5 nM, compared to a reported IC 50 value of 0.3 nM. The error bar represents the standard deviation of 10 replicates. The result is representative of 3 experiments. pounds on cell viability was assayed using an lactate dehydrogenase (LDH)-based cell toxicity kit (Promega). The CytoTox-One™ assay rapidly measures the release of LDH from cells with damaged membranes. LDH released into the culture medium is measured using a coupled enzymatic assay that results in the conversion of resazurin into a fluorescent resorufin product. The amount of fluorescence produced is proportional to the number of lysed cells. The percent toxicity caused by each compound was calculated using Excel software in relation to wells containing no compound. The results for one of the plates are presented in Figure 11 . Each point represents a single well on a 384-well plate. The few outliners above 5% may represent wells containing toxic compounds and thus were excluded from further validation.
The screening results for 25,000 compounds using the methodology described herein are presented in Figure 12 . All compounds were screened at a concentration of 1 µM using 1 µg/mL of tetracycline in 384-well plates. The percentage of inhibition was defined as the fraction of net activity of each compound after subtraction of the background (negative control without tetracycline) divided by the net positive control (positive control with tetracycline minus negative control). Furthermore, the inhibition was corrected (percent corrected inhibition) for cell toxicity by multiplying the percent inhibition by the fraction of live cells. The final results are illustrated in Figure 12 9. (a-c) Z′ factor calculated for each plate for 3 screens. Each day, 12 to 14 plates were screened, and for quality control, 1 plate containing only positive (half-plate containing media with tetracycline 1 µg/mL and DMSO 0.8%) and negative (half-plate containing media with DMSO 0.8%) controls were also included (the figure does not contain the result of this plate). Each point in the figure shows the Z′ value for each plate. The plates having Z′ values less than 0.4 were repeated.
ing observed in the scatter gram for some of the plates may be due to fluorescent compounds that might interfere with luminescence. We observed an edge effect ( Fig. 12 ) in both assay plates as well as in control plates, which might be due to evaporation. This edge effect can be minimized by increasing the humidity in the incubator (data not shown). Also, the transfer of 30 µL of conditioned media from these plates to other plates for LDH assays dramatically enhanced the edge effect caused by volume differences.
The scatter plot ( Fig. 12) was evaluated, and compounds with greater than 75% inhibition at 1 µM were subjected for verification of activity. Hits that caused more than 5% cell death were eliminated. Of the 60,000 compounds screened, 400 compounds were reassayed manually in triplicate at 3 different concentrations (10 nM, 100 nM, and 1 µM) using the same conditions that were used in the primary screen. A confirmation rate of 80% was found. Using a cutoff of 75% inhibition at 1 µM and a dose-dependent effect as criteria for selection, 236 compounds were confirmed as validated hits, for an overall hit rate of 0.39%. The possibility that apparent hits might merely inhibit cell growth without causing LDH leakage was tested using a cell titer kit (Promega).
DISCUSSION AND CONCLUSIONS
We have established a sensitive and quantitative HTS assay from which α-and γ-secretase-mediated cleavage of APP can be recorded. The assay has several attractive features. First, it can be used to find chemical modulators of not only α-and γ-secretases but also unknown proteases that might process APP, and it can identify novel protein modulators of APP processing. 27 This assay may be useful for the discovery of cell-permeable β-secretase inhibitors if adapted to different cell types that more robustly express β-secretase activity. On the other hand, the HEK cell line may be more suitable for finding activators of APP proteolysis: the alpha pathway is generally the major pathway in most cell types and is known to be inducible (e.g., by phorbol esters [28] [29] [30] [31] ). Second, this assay is very sensitive because VP16 is a strong transactivator, and Gal4 specifically recognizes its cognate promoter. The signal is strongly amplified because 1 released APP cytosolic tail will produce many luciferase molecules, and 1 luciferase molecule will turn over many substrate molecules to produce light. Third, this assay is much more conducive to HTS than ELISA, as it involves fewer steps and uses reagents that are readily available. In conclusion, we have developed a novel assay to monitor secretase processing of APP and successfully interfaced this assay with HTS. Several leads have been generated from this assay, and the mechanism of action of these inhibitors for APP processing is currently under investigation. 
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